## 1. Phylogeny

Interleukin-1 receptor-associated kinase 1 (IRAK1) is a member of a small but evolutionarily conserved family of serine/threonine kinases that mediate signal transduction downstream of innate immune receptors. Within this family, IRAK1 is closely related to IRAK2, IRAK3 (also known as IRAK‑M), and IRAK4, and these kinases have been preserved throughout vertebrate evolution because of their indispensable roles in regulating inflammation. Comparative sequence analyses reveal that IRAK1 harbors highly conserved catalytic motifs and regulatory domains that are maintained across a wide range of mammalian species, attesting to its essential function in rapidly propagating signals from Toll‑like receptors (TLRs) and interleukin‑1 receptors (IL‑1Rs) (bennett2022irak1andirak4 pages 1-2, patra2016recentprogressin pages 1-3). In the broader context of the kinome, IRAK1 is classified among receptor-interacting protein kinases with a canonical bilobal structure typical of serine/threonine kinases, and it shares similarities with other kinases that occupy critical positions in immune and inflammatory networks. Orthologs of IRAK1 have been identified in various species, implying that the underlying mechanisms of innate immune activation mediated by IRAK1 are conserved not only in mammalian systems but also in diverse vertebrates, lending support to the idea that IRAK1 and its homologs form an evolutionary core set of immune regulators (moret2020aresourcefor pages 23-26, patra2016recentprogressin pages 1-3).

## 2. Reaction Catalyzed

IRAK1 catalyzes the phosphorylation of specific serine and threonine residues on target proteins by transferring a phosphate group from ATP. The chemical reaction it mediates can be generally represented as:  
  ATP + [protein]-(Ser/Thr) → ADP + [protein]-(Ser/Thr)-phosphate + H⁺  
This phosphorylation is central to the mechanism by which IRAK1 propagates signals in TLR and IL‑1R pathways. In its canonical role, IRAK1 phosphorylates members of the Pellino family of E3 ubiquitin ligases (specifically PELI1, PELI2, and PELI3). The phosphorylation of these ligases induces conformational changes that significantly increase their E3 ubiquitin ligase activity, leading to the assembly of K63‑linked polyubiquitin chains on IRAK1 and other signaling intermediates. The process of polyubiquitination following IRAK1 activity is a key regulatory step as it facilitates the recruitment of the ubiquitin‑binding protein IKBKG/NEMO, which is essential for the formation of the TAK1 (MAP3K7)–TRAF6–IKK complex that ultimately activates NF‑κB (bahia2015interleukin1receptorassociated pages 17-17). In addition to Pellino proteins, IRAK1 phosphorylates the adaptor TIRAP, marking it for ubiquitination and degradation; this serves as a negative feedback mechanism to curtail prolonged signaling. Furthermore, phosphorylation of interferon regulatory factor 7 (IRF7) by IRAK1 is critical for its dimerization and nuclear translocation, events that lead to the transcriptional activation of type I interferon genes and the establishment of an antiviral state (seganish2016inhibitorsofinterleukin1 pages 1-6). Under conditions where IRAK1 undergoes sumoylation, the kinase translocates into the nucleus and phosphorylates STAT3, thus bridging cytoplasmic inflammatory signaling to direct regulation of gene transcription in the nucleus (chaudhary2015recentadvancesin pages 1-2, mcelroy2019interleukin1receptorassociatedkinase pages 21-25).

## 3. Cofactor Requirements

The catalytic function of IRAK1, as with most serine/threonine protein kinases, is critically dependent on the presence of divalent metal ion cofactors. Specifically, IRAK1 requires Mg²⁺ ions for its enzymatic activity. These metal ions coordinate with ATP within the kinase active site and stabilize the negative charges of the phosphate groups, thereby facilitating the proper positioning of ATP for the transfer of the γ‑phosphate to target serine or threonine residues (bahia2015interleukin1receptorassociated pages 17-17, wang2017crystalstructureof pages 6-6). Although in some biochemical systems alternative divalent metal ions such as Mn²⁺ may substitute, physiological studies strongly indicate that Mg²⁺ is the primary cofactor utilized by IRAK1 during its catalytic cycle. The dependence on Mg²⁺ is an intrinsic aspect of IRAK1’s operation in the cellular milieu, where magnesium concentrations are tightly regulated to support proper kinase function.

## 4. Substrate Specificity

Determining substrate specificity is key to understanding how IRAK1 orchestrates precise signaling events in response to immune challenges. Although no universally acknowledged linear consensus sequence has been defined for its substrates, IRAK1 exhibits a marked preference for several physiologically relevant proteins. The Pellino family proteins (PELI1, PELI2, and PELI3) are among the most thoroughly characterized substrates; IRAK1 phosphorylates these E3 ubiquitin ligases to trigger their activation, thereby promoting the formation of K63‑linked polyubiquitin chains (bahia2015interleukin1receptorassociated pages 17-17, seganish2016inhibitorsofinterleukin1 pages 19-22). In addition to the Pellino proteins, IRAK1 phosphorylates the adaptor protein TIRAP, which is subsequently ubiquitinated and degraded—a process that is hypothesized to serve as a mechanism for attenuating signal transduction after activation (mcelroy2019interleukin1receptorassociatedkinase pages 21-25). Another key substrate is IRF7, whose phosphorylation by IRAK1 is essential for its dimerization and nuclear import, thereby initiating a transcriptional program leading to type I interferon production (chaudhary2015recentadvancesin pages 1-2). Moreover, when IRAK1 is post‐translationally modified by SUMO, it undergoes nuclear translocation and engages STAT3 as a substrate; the phosphorylation of STAT3 is implicated in modulating transcriptional programs associated with cell survival and proliferation (pereira2023regulationofinnate pages 1-2). Although detailed mapping of exact amino acid motifs is still under investigation, the available data strongly suggest that IRAK1 preferentially targets substrate proteins involved in the regulation of immune and inflammatory processes, likely recognizing docking sequences or structural features that enable specific binding to its catalytic cleft (seganish2016inhibitorsofinterleukin1 pages 22-26, mcelroy2019interleukin1receptorassociatedkinase pages 21-25).

## 5. Structure

IRAK1 is characterized by a multidomain architecture that underpins both its catalytic function and its role as a scaffold within signaling complexes. At the N-terminus, IRAK1 contains a death domain (DD) comprising roughly 90–100 amino acids. This domain facilitates homotypic protein–protein interactions and is crucial for binding to adaptor proteins like MYD88, thereby mediating IRAK1’s recruitment to activated receptor complexes (mcelroy2019interleukin1receptorassociatedkinase pages 25-32, bahia2015interleukin1receptorassociated pages 1-2). Centrally, IRAK1 features a proline/serine/threonine-rich (ProST) region that acts as a flexible linker and serves as a major hub for autophosphorylation events during activation; extensive phosphorylation within this region is thought to drive conformational changes essential for transition from an inactive to an active state.

The catalytic core of IRAK1 lies in its C-terminal kinase domain, which adopts the canonical bilobal fold typical of many serine/threonine kinases. The N-terminal lobe generally contains a glycine-rich loop that is indispensable for ATP binding, while the C-terminal lobe forms the substrate-binding region. Structural studies, including crystallographic investigations of the IRAK1 kinase domain, have provided insights into key residues, such as a conserved tyrosine that functions as a gatekeeper; this residue is often a determinant of inhibitor specificity and distinguishes IRAK1 from its homolog IRAK4 (wang2017crystalstructureof pages 1-1, paul2020genome‐wideandstructural pages 8-9). Notably, unlike certain kinases that form stable homodimers in their inactive state, IRAK1 is predominantly monomeric until it is recruited to the myddosome. Within this higher-order complex, IRAK1 can heterodimerize with phosphorylated IRAK4, an event that is critical for its initial activation by IRAK4-mediated phosphorylation. In addition, post‑translational modifications such as sumoylation can alter the conformation of IRAK1 and promote its nuclear translocation, further highlighting the structural adaptability of this kinase (lange2021dimericstructureof pages 1-3, mcelroy2019interleukin1receptorassociatedkinase pages 25-32).

## 6. Regulation

The regulatory landscape governing IRAK1 activity is complex and finely tuned to allow rapid initiation and timely termination of immune signaling. A primary regulatory mechanism is the sequential phosphorylation cascade that begins upon ligand binding to TLRs or IL‑1Rs. The adaptor protein MYD88 first recruits IRAK1 to the receptor complex, where IRAK4 phosphorylates IRAK1. This initial phosphorylation event primes IRAK1 for extensive autophosphorylation, a modification that is essential for achieving full catalytic activation (bennett2022irak1andirak4 pages 1-2, patra2016recentprogressin pages 1-3). Once activated, IRAK1 phosphorylates its substrates to propagate the signal; however, these same phosphorylation events also set in motion negative regulatory feedback loops. For example, phosphorylation of TIRAP by IRAK1 leads to its ubiquitination and subsequent proteasomal degradation, effectively curtailing the signal to prevent chronic inflammation (mcelroy2019interleukin1receptorassociatedkinase pages 21-25).

In addition to phosphorylation, ubiquitination plays a key role in regulating IRAK1. The kinase phosphorylates the Pellino family E3 ubiquitin ligases, which then mediate K63‑linked polyubiquitination of IRAK1. These polyubiquitin chains serve as molecular scaffolds for the subsequent recruitment of IKBKG/NEMO, linking early receptor signaling to the activation of downstream kinases such as TAK1 and the IKK complex (seganish2016inhibitorsofinterleukin1 pages 22-26, bahia2015interleukin1receptorassociated pages 17-17). The ubiquitin-mediated modifications not only promote the assembly of signaling complexes but also can mark IRAK1 for degradation when conjugated via K48-linked chains, thereby contributing to signal termination.

Another regulatory mechanism involves sumoylation of IRAK1. When sumoylated, IRAK1 translocates from the cytoplasm into the nucleus where it phosphorylates substrates such as STAT3. This nuclear function not only extends IRAK1’s role beyond immediate inflammatory responses but also influences longer-term transcriptional regulation that can affect cell survival and proliferation (pereira2023regulationofinnate pages 1-2, reinhardt2023acriticalevaluation pages 22-23). Collectively, the regulation of IRAK1 is a dynamic process encompassing kinase activation by IRAK4, extensive autophosphorylation, ubiquitin- and SUMO-dependent modifications, and controlled degradation; these processes collectively ensure that innate immune responses are both robust and precisely modulated.

## 7. Function

IRAK1 is a critical mediator of innate immune signaling and plays a central role in initiating and coordinating cellular responses to pathogens. Upon engagement of pathogen-associated molecular patterns (PAMPs) by TLRs or binding of IL‑1 to its receptor, MYD88 recruits IRAK1 into the receptor complex. Activation of IRAK1 by IRAK4-dependent phosphorylation and subsequent autophosphorylation initiates a cascade of events that culminate in the activation of major transcription factors involved in inflammatory responses. A principal downstream effect is the phosphorylation of the Pellino family E3 ubiquitin ligases, which facilitates the assembly of K63‑linked ubiquitin chains and the subsequent recruitment of IKBKG/NEMO. This, in turn, enables the formation of the TAK1–TRAF6 complex and activation of IKK kinases, which phosphorylate IκB proteins leading to their degradation and freeing NF‑κB to translocate into the nucleus and stimulate the transcription of pro‑inflammatory cytokines such as IL‑1β, TNF‑α, IL‑6, and IL‑18 (bahia2015interleukin1receptorassociated pages 17-17, seganish2016inhibitorsofinterleukin1 pages 22-26).

In addition to promoting NF‑κB signaling, IRAK1 also phosphorylates IRF7, a transcription factor that, when activated, dimerizes and enters the nucleus to drive the expression of type I interferon genes. This function is particularly important in the antiviral response, enabling cells to establish an antiviral state through interferon production (chaudhary2015recentadvancesin pages 1-2). Furthermore, the capacity of IRAK1 to phosphorylate TIRAP not only contributes to the activation cascade but also ensures the subsequent termination of signaling by marking TIRAP for ubiquitination and degradation.

Beyond its classical cytoplasmic functions, IRAK1 can be modified by SUMO and translocated into the nucleus, where it phosphorylates STAT3. This nuclear activity links IRAK1 to the regulation of gene expression programs involved in cell survival, proliferation, and differentiation, thereby extending its functional influence to processes such as oncogenesis and tissue repair (pereira2023regulationofinnate pages 1-2, mcelroy2019interleukin1receptorassociatedkinase pages 25-32). Expressed broadly in diverse immune cells such as monocytes, macrophages, dendritic cells, T and B lymphocytes, and natural killer cells, IRAK1 is indispensable for a rapid and robust immune response and plays a key role in maintaining immune homeostasis. Dysregulation of IRAK1 has been linked to pathological conditions including autoimmune disorders, chronic inflammatory diseases, and certain cancers where aberrant NF‑κB signaling contributes to tumorigenesis (bennett2022irak1andirak4 pages 1-2, mcelroy2019interleukin1receptorassociatedkinase pages 21-25).

## 8. Other Comments

Given its central role in both inflammatory and antiviral signaling, IRAK1 has emerged as an attractive target for therapeutic intervention in a variety of immune‐ and inflammation‐related disorders. The hierarchical nature of IRAK1 activation—situated downstream of IRAK4—has led drug discovery efforts to explore not only direct IRAK1 kinase inhibitors but also indirect strategies aimed at disrupting its interactions within the myddosome complex. Several small molecule inhibitors have been developed that target IRAK1’s ATP binding site or interfere with its ability to phosphorylate downstream substrates; such compounds are often evaluated in parallel with IRAK4 inhibitors because blockade of upstream phosphorylation results in diminished IRAK1 activation (genung2017smallmoleculeinhibition pages 1-5, hatcher2020discoveryofa pages 5-6).

In addition, modulation of post‑translational modifications such as ubiquitination and sumoylation represents another promising strategy to regulate IRAK1 activity. Inhibitors that disrupt Pellino-mediated ubiquitination may attenuate the assembly of downstream signaling complexes, leading to reduced NF‑κB activation. Furthermore, the dual function of IRAK1 in both cytoplasmic and nuclear compartments underscores the possibility that selective inhibition of its nuclear functions (for instance, blocking STAT3 phosphorylation) could offer refined therapeutic windows with minimized systemic immunosuppression (liu2021leveragingdiversedata pages 69-74, wiese2020investigationalirak4inhibitors pages 17-21).

Beyond therapeutic inhibitor development, IRAK1’s dysregulation has been implicated in a broad array of inflammatory pathologies, including rheumatoid arthritis, systemic lupus erythematosus, and various cancers wherein chronic inflammation plays a role in disease progression. Characterization of unique mutations or alterations in expression levels of IRAK1 in such conditions can potentially serve as biomarkers for disease prognosis or as indicators for personalized therapy approaches. Current research is increasingly focusing on the network of interactions between IRAK1 and other immune modulators, as well as understanding how species and cell type-specific differences in IRAK1 function might impact the efficacy of targeted therapies (reinhardt2023acriticalevaluation pages 22-23, zarrin2021kinaseinhibitionin pages 8-9).

Additionally, structural and biophysical studies continue to elucidate the molecular details governing IRAK1’s substrate recognition and activation dynamics. Such insights not only further our understanding of innate immune signaling but also feed directly into the rational design of next-generation inhibitors that are both potent and highly selective for IRAK1. As our knowledge of IRAK1’s multifaceted roles expands, so too does the prospect of manipulating its regulatory mechanisms to finely tune immune responses in a clinical setting.

## 9. References

1. bahia2015interleukin1receptorassociated pages 17-17
2. bennett2022irak1andirak4 pages 1-2
3. chaudhary2015recentadvancesin pages 1-2
4. genung2017smallmoleculeinhibition pages 1-5
5. hatcher2020discoveryofa pages 5-6
6. lange2021dimericstructureof pages 1-3
7. liu2021leveragingdiversedata pages 69-74
8. mcelroy2019interleukin1receptorassociatedkinase pages 21-25
9. mcelroy2019interleukin1receptorassociatedkinase pages 25-32
10. moret2020aresourcefor pages 23-26
11. patra2016recentprogressin pages 1-3
12. patra2016recentprogressin pages 13-15
13. paul2020genome‐wideandstructural pages 8-9
14. pereira2023regulationofinnate pages 1-2
15. reinhardt2023acriticalevaluation pages 22-23
16. seganish2016inhibitorsofinterleukin1 pages 1-6
17. seganish2016inhibitorsofinterleukin1 pages 19-22
18. seganish2016inhibitorsofinterleukin1 pages 22-26
19. southekal2021integrativeanalysisof pages 19-25
20. totzke2017targetingtransforminggrowth pages 201-204
21. vollmer2017themechanismof pages 1-3
22. vollmer2017themechanismof pages 3-5
23. vollmer2017themechanismof pages 5-8
24. wang2017crystalstructureof pages 1-1
25. wang2017crystalstructureof pages 6-6
26. wiese2020investigationalirak4inhibitors pages 17-21
27. zarrin2021kinaseinhibitionin pages 8-9
28. bahia2015interleukin1receptorassociated pages 1-2
29. bahia2015interleukin1receptorassociated pages 3-4
30. bahia2015interleukin1receptorassociated pages 8-11

References

1. (bahia2015interleukin1receptorassociated pages 17-17): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
2. (bennett2022irak1andirak4 pages 1-2): Joshua Bennett and Daniel T. Starczynowski. Irak1 and irak4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 29:8-19, Nov 2022. URL: https://doi.org/10.1097/moh.0000000000000693, doi:10.1097/moh.0000000000000693. This article has 77 citations and is from a peer-reviewed journal.
3. (chaudhary2015recentadvancesin pages 1-2): Divya Chaudhary, Shaughnessy Robinson, and Donna L. Romero. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (irak4) as a therapeutic target for inflammation and oncology disorders. Journal of medicinal chemistry, 58 1:96-110, Jan 2015. URL: https://doi.org/10.1021/jm5016044, doi:10.1021/jm5016044. This article has 114 citations and is from a highest quality peer-reviewed journal.
4. (genung2017smallmoleculeinhibition pages 1-5): N.E. Genung and K.M. Guckian. Small molecule inhibition of interleukin-1 receptor-associated kinase 4 (irak4). Progress in Medicinal Chemistry, 56:117-163, Jan 2017. URL: https://doi.org/10.1016/bs.pmch.2016.11.004, doi:10.1016/bs.pmch.2016.11.004. This article has 24 citations and is from a peer-reviewed journal.
5. (hatcher2020discoveryofa pages 5-6): John M. Hatcher, Guang Yang, Li Wang, Scott B. Ficarro, Sara Buhrlage, Hao Wu, Jarrod A. Marto, Steven P. Treon, and Nathanael S. Gray. Discovery of a selective, covalent irak1 inhibitor with antiproliferative activity in myd88 mutated b-cell lymphoma. ACS Medicinal Chemistry Letters, 11:2238-2243, Oct 2020. URL: https://doi.org/10.1021/acsmedchemlett.0c00378, doi:10.1021/acsmedchemlett.0c00378. This article has 23 citations and is from a peer-reviewed journal.
6. (lange2021dimericstructureof pages 1-3): Sven M. Lange, Marina I. Nelen, Philip Cohen, and Yogesh Kulathu. Dimeric structure of the pseudokinase irak3 suggests an allosteric mechanism for negative regulation. Structure, 29:238-251.e4, Mar 2021. URL: https://doi.org/10.1016/j.str.2020.11.004, doi:10.1016/j.str.2020.11.004. This article has 33 citations and is from a domain leading peer-reviewed journal.
7. (liu2021leveragingdiversedata pages 69-74): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
8. (mcelroy2019interleukin1receptorassociatedkinase pages 21-25): William T. McElroy. Interleukin-1 receptor-associated kinase 4 (irak4) inhibitors: an updated patent review (2016-2018). Expert Opinion on Therapeutic Patents, 29:243-259, Mar 2019. URL: https://doi.org/10.1080/13543776.2019.1597850, doi:10.1080/13543776.2019.1597850. This article has 55 citations and is from a peer-reviewed journal.
9. (mcelroy2019interleukin1receptorassociatedkinase pages 25-32): William T. McElroy. Interleukin-1 receptor-associated kinase 4 (irak4) inhibitors: an updated patent review (2016-2018). Expert Opinion on Therapeutic Patents, 29:243-259, Mar 2019. URL: https://doi.org/10.1080/13543776.2019.1597850, doi:10.1080/13543776.2019.1597850. This article has 55 citations and is from a peer-reviewed journal.
10. (moret2020aresourcefor pages 23-26): Nienke Moret, Changchang Liu, Benjamin M. Gyori, John A. Bachman, Albert Steppi, Clemens Hug, Rahil Taujale, Liang-Chin Huang, Matthew E. Berginski, Shawn M. Gomez, Natarajan Kannan, and Peter K. Sorger. A resource for exploring the understudied human kinome for research and therapeutic opportunities. BioRxiv, Apr 2020. URL: https://doi.org/10.1101/2020.04.02.022277, doi:10.1101/2020.04.02.022277. This article has 28 citations.
11. (patra2016recentprogressin pages 1-3): M. C. Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 44 citations and is from a peer-reviewed journal.
12. (patra2016recentprogressin pages 13-15): M. C. Patra and Sangdun Choi. Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules, Nov 2016. URL: https://doi.org/10.3390/molecules21111529, doi:10.3390/molecules21111529. This article has 44 citations and is from a peer-reviewed journal.
13. (paul2020genome‐wideandstructural pages 8-9): Anindita Paul and Narayanaswamy Srinivasan. Genome‐wide and structural analyses of pseudokinases encoded in the genome of arabidopsis thaliana provide functional insights. Proteins: Structure, Function, and Bioinformatics, 88:1620-1638, Aug 2020. URL: https://doi.org/10.1002/prot.25981, doi:10.1002/prot.25981. This article has 12 citations.
14. (pereira2023regulationofinnate pages 1-2): Milton Pereira and Ricardo T. Gazzinelli. Regulation of innate immune signaling by irak proteins. Frontiers in Immunology, Feb 2023. URL: https://doi.org/10.3389/fimmu.2023.1133354, doi:10.3389/fimmu.2023.1133354. This article has 54 citations and is from a peer-reviewed journal.
15. (reinhardt2023acriticalevaluation pages 22-23): Ronja Reinhardt and Thomas A Leonard. A critical evaluation of protein kinase regulation by activation loop autophosphorylation. eLife, Jul 2023. URL: https://doi.org/10.7554/elife.88210, doi:10.7554/elife.88210. This article has 43 citations and is from a domain leading peer-reviewed journal.
16. (seganish2016inhibitorsofinterleukin1 pages 1-6): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
17. (seganish2016inhibitorsofinterleukin1 pages 19-22): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
18. (seganish2016inhibitorsofinterleukin1 pages 22-26): W. Michael Seganish. Inhibitors of interleukin-1 receptor-associated kinase 4 (irak4): a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 26:917-932, Jun 2016. URL: https://doi.org/10.1080/13543776.2016.1202926, doi:10.1080/13543776.2016.1202926. This article has 37 citations and is from a peer-reviewed journal.
19. (southekal2021integrativeanalysisof pages 19-25): S Southekal. Integrative analysis of multi-omics kinome data and virtual screening of identified targets with pan-cancer application. Unknown journal, 2021.
20. (totzke2017targetingtransforminggrowth pages 201-204): J Totzke. Targeting transforming growth factor beta-activated kinase 1 as a therapeutic strategy in cancer and immune disease. Unknown journal, 2017.
21. (vollmer2017themechanismof pages 1-3): Stefan Vollmer, Sam Strickson, Tinghu Zhang, Nathanael Gray, Katherine L. Lee, Vikram R. Rao, and Philip Cohen. The mechanism of activation of irak1 and irak4 by interleukin-1 and toll-like receptor agonists. Biochemical Journal, 474:2027-2038, Jun 2017. URL: https://doi.org/10.1042/bcj20170097, doi:10.1042/bcj20170097. This article has 105 citations and is from a domain leading peer-reviewed journal.
22. (vollmer2017themechanismof pages 3-5): Stefan Vollmer, Sam Strickson, Tinghu Zhang, Nathanael Gray, Katherine L. Lee, Vikram R. Rao, and Philip Cohen. The mechanism of activation of irak1 and irak4 by interleukin-1 and toll-like receptor agonists. Biochemical Journal, 474:2027-2038, Jun 2017. URL: https://doi.org/10.1042/bcj20170097, doi:10.1042/bcj20170097. This article has 105 citations and is from a domain leading peer-reviewed journal.
23. (vollmer2017themechanismof pages 5-8): Stefan Vollmer, Sam Strickson, Tinghu Zhang, Nathanael Gray, Katherine L. Lee, Vikram R. Rao, and Philip Cohen. The mechanism of activation of irak1 and irak4 by interleukin-1 and toll-like receptor agonists. Biochemical Journal, 474:2027-2038, Jun 2017. URL: https://doi.org/10.1042/bcj20170097, doi:10.1042/bcj20170097. This article has 105 citations and is from a domain leading peer-reviewed journal.
24. (wang2017crystalstructureof pages 1-1): Li Wang, Qi Qiao, Ryan Ferrao, Chen Shen, John M. Hatcher, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Crystal structure of human irak1. Proceedings of the National Academy of Sciences, 114:13507-13512, Dec 2017. URL: https://doi.org/10.1073/pnas.1714386114, doi:10.1073/pnas.1714386114. This article has 80 citations.
25. (wang2017crystalstructureof pages 6-6): Li Wang, Qi Qiao, Ryan Ferrao, Chen Shen, John M. Hatcher, Sara J. Buhrlage, Nathanael S. Gray, and Hao Wu. Crystal structure of human irak1. Proceedings of the National Academy of Sciences, 114:13507-13512, Dec 2017. URL: https://doi.org/10.1073/pnas.1714386114, doi:10.1073/pnas.1714386114. This article has 80 citations.
26. (wiese2020investigationalirak4inhibitors pages 17-21): Michael D. Wiese, Arkady T. Manning-Bennett, and Ahmad Y. Abuhelwa. Investigational irak-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs, 29:475-482, Apr 2020. URL: https://doi.org/10.1080/13543784.2020.1752660, doi:10.1080/13543784.2020.1752660. This article has 50 citations and is from a peer-reviewed journal.
27. (zarrin2021kinaseinhibitionin pages 8-9): Ali A. Zarrin, Katherine Bao, Patrick Lupardus, and Domagoj Vucic. Kinase inhibition in autoimmunity and inflammation. Nature Reviews Drug Discovery, 20:39-63, Oct 2021. URL: https://doi.org/10.1038/s41573-020-0082-8, doi:10.1038/s41573-020-0082-8. This article has 384 citations and is from a highest quality peer-reviewed journal.
28. (bahia2015interleukin1receptorassociated pages 1-2): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
29. (bahia2015interleukin1receptorassociated pages 3-4): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.
30. (bahia2015interleukin1receptorassociated pages 8-11): Malkeet Singh Bahia, Maninder Kaur, Pragati Silakari, and Om Silakari. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cellular Signalling, 27:1039-1055, Jun 2015. URL: https://doi.org/10.1016/j.cellsig.2015.02.025, doi:10.1016/j.cellsig.2015.02.025. This article has 57 citations and is from a peer-reviewed journal.